ライフサイエンスコーパス: Candida glabrata

1 tance among some Candida species, especially Candida glabrata.

2 are conserved in the distantly related yeast Candida glabrata.

3 dida krusei, Candida tropicalis, and perhaps Candida glabrata.

4 tes of Candida, including Candida krusei and Candida glabrata.

5 ans, Candida tropicalis, Candida krusei, and Candida glabrata.

6 e MTI and MTII genes of the pathogenic yeast Candida glabrata.

7 9% (95% CI, 99.7%-100.0%) for Candida krusei/Candida glabrata.

8 by CST using purified complexes derived from Candida glabrata.

9 nd voriconazole (from 6.1% to 18.4%) against Candida glabrata.

10 ed treatment for invasive candidiasis due to Candida glabrata.

11 rom relaxation of constraint specifically in Candida glabrata.

12 spleens of mice infected intravenously with Candida glabrata.

13 tment of bloodstream infections (BSI) due to Candida glabrata.

14 s of Candida including the distantly related Candida glabrata.

15 ortion of persisters in Candida albicans and Candida glabrata.

16 ent repression of RPs in the fungal pathogen Candida glabrata.

17 a eukaryotic FMNAT from the pathogenic yeast Candida glabrata.

18 attributed to trailing growth observed with Candida glabrata.

19 d in the clinically important human pathogen Candida glabrata.

20 (DB) > white (W), similar to the result for Candida glabrata.

21 g 74 yeast isolates (14 Candida albicans, 10 Candida glabrata, 10 Candida tropicalis, 10 Candida krus

22 albicans, 14.4% Candida parapsilosis, 13.4% Candida glabrata, 10.1% Candida tropicalis, 2.4% Candida

23 lbicans (52%), Candida parapsilosis (23.7%), Candida glabrata (12.7%), Candida tropicalis (5.8%), Can

24 5 isolates of Candida krusei, 3 isolates of Candida glabrata, 2 isolates of Saccharomyces cerevisiae

25 here were a total of 41 Candida albicans, 23 Candida glabrata, 20 Candida parapsilosis, 9 Candida tro

26 isolates of Candida (42 Candida albicans, 25 Candida glabrata, 22 Candida parapsilosis, 14 Candida tr

27 sed by Candida albicans (52.7%), followed by Candida glabrata (25.6%) and Candida tropicalis (16.3%).

28 equently isolated species (38%), followed by Candida glabrata (29%), Candida parapsilosis (17%), and

29 he most frequently misidentified species was Candida glabrata (37% of all discrepant identifications)

30 (4 mutants), Candida krusei (3 mutants), and Candida glabrata (55 mutants).

31 Live Candida tropicalis, Candida glabrata, a nongerminating strain of C. albicans

32 the characterization of the SNF1 homolog of Candida glabrata, a pathogenic yeast phylogenetically re

33 heterologously expressed C. albicans ALS3 in Candida glabrata, a yeast that lacks a close ALS3 orthol

34 thogenic yeasts such as Candida albicans and Candida glabrata adhere to medical devices and form drug

35 Candida glabrata adhered avidly to human epithelial cell

36 The yeast pathogen Candida glabrata adheres avidly to cultured human epithe

37 the potentially multidrug-resistant pathogen Candida glabrata against anidulafungin and fluconazole.

38 Rapid transcriptional autoactivation of the Candida glabrata AMT1 copper metalloregulatory transcrip

39 Adherence of Candida glabrata, an opportunistic yeast pathogen, to ho

40 ere we present the structures of Atp11p from Candida glabrata and Atp12p from Paracoccus denitrifican

41 carriage, showed an increased proportion of Candida glabrata and C. tropicalis.

42 potentially fluconazole-resistant organisms (Candida glabrata and Candida krusei) to those with other

43 Is were due to Candida albicans, followed by Candida glabrata and Candida parapsilosis (15%), Candida

44 Categorical agreement was lowest for Candida glabrata and Candida tropicalis with both test s

45 and caspofungin of 601 invasive isolates of Candida glabrata and grouped the isolates by geographic

46 ole of 559 bloodstream infection isolates of Candida glabrata and grouped the isolates by patient age

47 642 bloodstream infection (BSI) isolates of Candida glabrata and grouped the isolates by patient age

48 plies most directly to fluconazole-resistant Candida glabrata and is variable among other species of

49 red in several Candida species, most notably Candida glabrata and more recently Candida auris.

50 between four yeast strains from two species, Candida glabrata and Saccharomyces cerevisiae (haploid s

51 Comparative genomic analyses of Candida glabrata and Saccharomyces cerevisiae suggest ma

52 da albicans, 26 of Candida tropicalis, 23 of Candida glabrata, and 27 of other yeasts, were tested by

53 calis, Candida parapsilosis, Candida krusei, Candida glabrata, and Candida albicans).

54 Candida albicans, Candida glabrata, and Candida parapsilosis endophthalmit

55 Candida tropicalis, Candida guilliermondii, Candida glabrata, and Candida parapsilosis.

56 icans, Candida krusei, Candida parapsilosis, Candida glabrata, and Candida tropicalis as well as othe

57 da albicans, one Histoplasma capsulatum, one Candida glabrata, and one Fusarium species isolate); thr

58 es were found in CPT for Candida tropicalis, Candida glabrata, and other common pathogenic fungi.

59 th meningoencephalitis and colitis caused by Candida glabrata, and Q295* for the patient with Candida

60 -rich region of epithelial adhesin (Epa1) of Candida glabrata, and the carboxyl region of the cell wa

61 nt forms of the Tom40 protein from the yeast Candida glabrata, and truncated constructs lacking the N

62 PS on YPD-CuSO(4) is also similar to that in Candida glabrata, and we hypothesize that this is due to

63 icans, 27 Candida tropicalis, 22 Torulopsis (Candida) glabrata, and 29 other yeast isolates were test

64 Infections with the azole-refractory yeast Candida glabrata are now commonly treated with the echin

65 Candida albicans and Candida glabrata are predominant fungi associated with o

66 r modifying genes from the pathogenic fungus Candida glabrata as well as a companion vector for compl

67 the established pathogens Candida krusei and Candida glabrata, as a species of Candida with reduced s

68 th of bacteria (Escherichia coli) and yeast (Candida glabrata) at micromolar concentrations.

69 plant recipients that developed breakthrough Candida glabrata bloodstream infections while receiving

70 ne expression by diverse microbes, including Candida glabrata, Bordetella pertussis, Escherichia coli

71 ich are closely related to and identified as Candida glabrata by phenotypic assays.

72 recognition of an emerging fungal pathogen, Candida glabrata, by the human NK cytotoxic receptor NKp

73 Candida albicans and Candida glabrata can be identified in blood culture bott

74 xed PCR assay detecting Candida albicans and Candida glabrata (CAN-PCR) was compared with the Affirm

75 ccharomyces from each other, as well as from Candida glabrata, Candida albicans, and Blastomyces derm

76 mplemented by the Ure2p of Candida albicans, Candida glabrata, Candida kefyr, Candida maltosa, Saccha

77 ve isolates per species of Candida albicans, Candida glabrata, Candida parapsilosis, Aspergillus fumi

78 the rRNA gene to identify Candida albicans, Candida glabrata, Candida parapsilosis, Candida tropical

79 er a Candida 7-plex panel (Candida albicans, Candida glabrata, Candida tropicalis, Candida parapsilos

80 The opportunistic pathogen Candida glabrata causes significant disease in humans.

81 2 and pathogenic Candida albicans CaUpc2 and Candida glabrata CgUpc2 to AR1b and SRE/AR1c elements.

82 Candida glabrata chorioamnionitis presents unique manage

83 We hypothesized that species of the Candida glabrata clade and species with phenotypic trait

84 Candida glabrata colonization is common in patients rece

85 In addition, it is demonstrated that Candida glabrata colonizes the oral cavities of elderly

86 charomyces cerevisiae and the human pathogen Candida glabrata directly bind to structurally diverse d

87 Candida glabrata emerged in the last decade as a common

88 mbers functionally identified as adhesins in Candida glabrata (Epa1, Epa6 and Epa7) bind to ligands c

89 C. albicans and Candida glabrata express the ALS (agglutinin-like sequen

90 The fungal pathogen Candida glabrata expresses a protein homologous to Ybp1

91 e divergence of Saccharomyces cerevisiae and Candida glabrata, followed by massive gene loss that res

92 Expression microarray analysis of Candida glabrata following phagocytosis by human neutrop

93 impact of the treatment of fungemias due to Candida glabrata from a hospital perspective using three

94 he presumptive identification of Torulopsis (Candida) glabrata from other common clinical isolates of

95 The Candida glabrata genome encodes at least 23 members of t

96 The human pathogenic yeast Candida glabrata harbors more than 20 surface-exposed, e

97 The fungal pathogen Candida glabrata has emerged as a major health threat si

98 Candida glabrata has emerged as an important nosocomial

99 Although Candida glabrata has emerged in recent years as a major

100 Candida glabrata has emerged in recent years as a signif

101 vival, and virulence in the pathogenic yeast Candida glabrata Here, we demonstrate PI3-kinase (CgVps3

102 npoint a single species, the fungal pathogen Candida glabrata, in which a trans mutation has occurred

103 odulating organism virulence using ace2Delta Candida glabrata infection in neutropenic mice.

104 Cytokine-mediated host defense against Candida glabrata infection was compared to that against

105 o protect against neurological degeneration, Candida glabrata infection, and possibly to enhance reve

106 Vaginal Candida glabrata infections have increased significantly

107 The pathogenesis of Candida glabrata infections is poorly understood.

108 The yeast pathogen Candida glabrata is a nicotinamide adenine dinucleotide

109 Candida glabrata is a yeast pathogen of humans.

110 The pathogenic yeast Candida glabrata is able to bind in vitro to human epith

111 The Amt1 transcription factor from Candida glabrata is activated by the formation of a tetr

112 The fungus Candida glabrata is an important and increasingly common

113 Candida glabrata is an important fungal pathogen of huma

114 Candida glabrata is an important opportunistic pathogen

115 The yeast Candida glabrata is an opportunistic pathogen of humans.

116 ctor from the opportunistic pathogenic yeast Candida glabrata is dependent on rapid metal-induced DNA

117 host colonization, the human fungal pathogen Candida glabrata is known to utilize a large family of h

118 linical impact of voriconazole resistance in Candida glabrata is not well described.

119 rs ACE1 (Saccharomyces cerevisiae) and AMT1 (Candida glabrata) is present in the promoters of three m

120 invasive candidiasis and candidemia due to a Candida glabrata isolate that developed resistance to al

121 We analyzed 1,598 Candida glabrata isolates for the presence of the crypti

122 The antifungal susceptibilities of 79 oral Candida glabrata isolates to fluconazole and voriconazol

123 s for testing of the susceptibilities of 235 Candida glabrata isolates to fluconazole and voriconazol

124 ) and included 303 C. albicans isolates, 153 Candida glabrata isolates, 70 Candida tropicalis isolate

125 p to six missed episodes of candidemia (four Candida glabrata isolates, one C. albicans isolate, and

126 Candida glabrata, like Candida albicans, is an opportuni

127 We observed that the yeast Candida glabrata lost the gene encoding a phosphate-repr

128 crystal structures of the Vik1 ortholog from Candida glabrata may provide insight into this mechanism

129 st isolates were Candida albicans (n = 420), Candida glabrata (n = 112), Candida parapsilosis (n = 30

130 solates included Candida albicans (n = 161), Candida glabrata (n = 41), Candida tropicalis (n = 35),

131 s identified were Candida albicans (n = 85), Candida glabrata (n = 63), and Candida parapsilosis (n =

132 solates included Candida albicans (n = 486), Candida glabrata (n = 96), Candida tropicalis (n = 51),

133 tivity of VT-1161 against Candida krusei and Candida glabrata, pathogens that are intrinsically resis

134 ated the performance of the Candida albicans/Candida glabrata peptide nucleic acid fluorescent in sit

135 The yeast Candida glabrata rapidly autoactivates transcription of

136 albicans, heterologous expression of HYR1 in Candida glabrata rendered the organism more resistant to

137 creen assay to accurately detect isolates of Candida glabrata resistant to the azole antifungal agent

138 We report a case of Candida glabrata sepsis associated with chorioamnionitis

139 Six yeast isolates (all Candida glabrata) showing caspofungin MIC values of >or=

140 Candida glabrata STE12 can functionally complement the n

141 The Candida glabrata STE12 homologue was cloned.

142 Candida glabrata STE12 is therefore the first virulence

143 Clinical echinocandin resistance among Candida glabrata strains is increasing, especially in th

144 nservation of this quality control system in Candida glabrata suggests that many pathogenic species o

145 C. albicans and Candida glabrata suppressed ROS production by phagocytes

146 Candida glabrata switches spontaneously at high frequenc

147 cer or fungemia caused by the DA nonproducer Candida glabrata than in patients with cancer or fungemi

148 ularly relevant for pathogenic fungi such as Candida glabrata that are closely related to S. cerevisi

149 Candida albicans and Candida glabrata that were resistant to anidulafungin, c

150 identified only 102 (82%) of 124 isolates of Candida glabrata, the predictive value of an MIS identif

151 The adherence of Candida glabrata to host cells is mediated, at least in

152 The pathogenicity of Candida glabrata to patients remains poorly understood f

153 The ability of the yeast Candida glabrata to survive copper insult requires rapid

154 Seven isolates of Candida glabrata, two isolates of Candida parapsilosis,

155 on in Saccharomyces cerevisiae, but Ure2p of Candida glabrata (Ure2(glabrata)) cannot, even though th

156 nsertional mutagenesis of the yeast pathogen Candida glabrata using the bacterial transposon Tn7.

157 d proteinase activity, play no known role in Candida glabrata virulence.

158 e CBF1 (centromere binding factor 1) gene of Candida glabrata was cloned by functional complementatio

159 dentified throughout the reading period, but Candida glabrata was difficult to differentiate from oth

160 However, Candida glabrata was the most commonly isolated species

161 nsis, a yeast species genetically related to Candida glabrata, was described following its isolation

162 rtance of SUMOylation in the human pathogen, Candida glabrata We identified the enzymes involved in s

163 d decrease the cost of the identification of Candida glabrata, we evaluated four methods for the dete

164 Known concentrations of Candida albicans and Candida glabrata were each added to a set of vials.

165 a albicans and Candida tropicalis (those for Candida glabrata were unchanged) within the 4-year span.

166 olates were echinocandin-resistant, and 9 (8 Candida glabrata) were multidrug resistant to both fluco

167 Candida glabrata, which can become resistant to fluconaz

168 relative proportion of infections caused by Candida glabrata, which has reduced susceptibility to fl

169 her-level resistance has been reported among Candida glabrata, which is also frequently resistant to

170 ous proteins in Saccharomyces cerevisiae and Candida glabrata, whose sequences have diverged to a deg

171 C), and posaconazole (PSZ) in 24 isolates of Candida glabrata with decreased susceptibility to azoles